<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03077685</url>
  </required_header>
  <id_info>
    <org_study_id>NANOPAC-2016-05</org_study_id>
    <nct_id>NCT03077685</nct_id>
  </id_info>
  <brief_title>Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma</brief_title>
  <official_title>Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanOlogy, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Biotest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NanOlogy, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally&#xD;
      advanced pancreatic adenocarcinoma via direct intratumoral injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this open-label, dose-escalating, Phase IIa trial, subjects with locally advanced&#xD;
      pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate&#xD;
      Paclitaxel) via endoscopic ultrasound-guided direct injection.&#xD;
&#xD;
      Subjects will be enrolled in sequential cohorts of NanoPac® at escalating doses, at a volume&#xD;
      based on up to 20% of calculated tumor volume (with a maximum injection volume of 5 mL per&#xD;
      subject). Each cohort will have three subjects, with cohorts enrolled sequentially starting&#xD;
      at the lowest concentration. Following DSMB review of the cohort data, the next cohort may&#xD;
      begin enrolling, an additional three subjects at the current dose may be enrolled, or if the&#xD;
      first dose does not provide adequate safety and tolerability the study may be halted.&#xD;
&#xD;
      The dose determined to be most suitable for further evaluation, defined as the highest dose&#xD;
      with an acceptable safety and tolerability profile as determined by the Data Safety&#xD;
      Monitoring Board (DSMB), will be the dose used in the second phase of the study which will&#xD;
      enroll 22 additional subjects who will receive two injections of NanoPac® at the same dose&#xD;
      one month apart. In the third phase of the study, up to 30 subjects will receive up to four&#xD;
      injections of NanoPac at the same dose, one month apart.&#xD;
&#xD;
      Plasma samples will be taken at various time points on the day of NanoPac® injection as well&#xD;
      as once at each of the study visits, to characterize the pharmacokinetics (PK) of&#xD;
      intratumoral NanoPac®.&#xD;
&#xD;
      Subjects will be followed for 12 months after NanoPac® injection for safety, overall survival&#xD;
      (OS), progression-free survival (PFS), CA-19-9 levels, carcinoembryonic antigen (CEA) levels,&#xD;
      reduction in pain, and tumor response to therapy (as shown by imaging).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label, dose-escalating, Phase IIa trial. Subjects will be enrolled in sequential cohorts of NanoPac® at a volume up to 20% of tumor volume (maximum injection volume of 5 mL per subject). Each cohort will have 3 subjects, with cohorts enrolled sequentially starting at the lowest concentration. Following DSMB review of the cohort data, the next cohort may begin enrolling. The highest dose with an acceptable safety and tolerability profile will be the dose used in the second phase of the study which will enroll 22 additional subjects to receive 2 NanoPac® injections one month apart and 30 additional subjects to receive 4 NanoPac® injections one month apart.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (safety and tolerability)</measure>
    <time_frame>Up to 6 (six) months after NanoPac® injection</time_frame>
    <description>Treatment Emergent Adverse Events will include laboratory assessments, physical examination findings, and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) of NanoPac®</measure>
    <time_frame>Up to 6 (six) months after NanoPac® injection</time_frame>
    <description>Pharmacokinetic (PK) samples will be taken on Day 1 prior to injection, and at 1, 2, 4, 6, and 24 hours post-injection, and again at all study visits post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Peak plasma concentration (Cmax) of NanoPac®</measure>
    <time_frame>Up to 6 (six) months after NanoPac® injection</time_frame>
    <description>Pharmacokinetic (PK) samples will be taken on Day 1 prior to injection, and at 1, 2, 4, 6, and 24 hours post-injection, and again at all study visits post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time at which peak plasma concentration is observed (Tmax) of NanoPac®</measure>
    <time_frame>Up to 6 (six) months after NanoPac® injection</time_frame>
    <description>Pharmacokinetic (PK) samples will be taken on Day 1 prior to injection, and at 1, 2, 4, 6, and 24 hours post-injection, and again at all study visits post-injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response (RECIST)</measure>
    <time_frame>Baseline and every 3 (three) months after NanoPac® injection, up to 12 months</time_frame>
    <description>Tumor burden at 3 months after NanoPac® injection will be compared with baseline tumor burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>Baseline and 3 (three) months after NanoPac® injection</time_frame>
    <description>Pain scores will be measured using a visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor markers</measure>
    <time_frame>Baseline, 3 (three) months, and 6 (six) months after NanoPac® injection</time_frame>
    <description>Tumor markers measured will include CEA and CA19-9</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Locally Advanced Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Dose Escalation: NanoPac® 6 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumorally injected NanoPac® at a volume of up to 20% tumor volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: NanoPac® 10 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumorally injected NanoPac® at a volume of up to 20% tumor volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation: NanoPac® 15 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumorally injected NanoPac® at a volume of up to 20% tumor volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second Phase: NanoPac® at Best Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® administrations, with the second injection administered one month after the first injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third Phase: NanoPac® at Best Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumorally injected NanoPac® at a volume of up to 20% tumor volume. The dose administered in the third phase will be determined during the dose escalation phase. Subjects will receive four NanoPac® administrations, with the injections administered one month apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NanoPac®</intervention_name>
    <description>Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.</description>
    <arm_group_label>Dose Escalation: NanoPac® 10 mg/mL</arm_group_label>
    <arm_group_label>Dose Escalation: NanoPac® 15 mg/mL</arm_group_label>
    <arm_group_label>Dose Escalation: NanoPac® 6 mg/mL</arm_group_label>
    <arm_group_label>Second Phase: NanoPac® at Best Dose</arm_group_label>
    <arm_group_label>Third Phase: NanoPac® at Best Dose</arm_group_label>
    <other_name>Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent;&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Histologically/cytologically confirmed locally advanced pancreatic adenocarcinoma; at&#xD;
             least one lesion with a diameter of at least 1.5 cm but no more than 6 cm as&#xD;
             documented via imaging (within 6 weeks of Screening);&#xD;
&#xD;
          -  Subject not a candidate for surgery;&#xD;
&#xD;
          -  Completion of at least one standard of care IV chemotherapy course for subjects in the&#xD;
             dose escalation phase of the study. IV chemotherapy will be initiated prior to first&#xD;
             NanoPac injection for subjects in the second and third phases. Hematologic recovery&#xD;
             must be confirmed prior to study entry;&#xD;
&#xD;
          -  Performance Status (ECOG) 0-1 at study entry;&#xD;
&#xD;
          -  Life expectancy of at least 3 months;&#xD;
&#xD;
          -  Adequate marrow, liver, and renal function at study entry:&#xD;
&#xD;
               -  ANC ≥ 1.5 x 109/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.5 grams/dL&#xD;
&#xD;
               -  Platelets ≥ 75 x 109/L&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5x institutional ULN&#xD;
&#xD;
               -  AST/ ALT ≤ 2.5x institutional ULN&#xD;
&#xD;
               -  Creatinine ≤ 1.5x institutional ULN&#xD;
&#xD;
          -  Effective contraception if the risk of conception exists.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Thrombotic or embolic events;&#xD;
&#xD;
          -  Acute or subacute intestinal occlusion;&#xD;
&#xD;
          -  History of inflammatory bowel disease;&#xD;
&#xD;
          -  Known hypersensitivity to study drugs;&#xD;
&#xD;
          -  Known drug or alcohol abuse;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Previous or concurrent history of non-pancreatic malignancy except for non-melanoma&#xD;
             skin cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shelagh Verco, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vice President, Clinical Development, US Biotest, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shelagh Verco, PhD</last_name>
    <phone>805-595-1300</phone>
    <email>shelagh.verco@usbiotest.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gere diZerega, MD</last_name>
    <phone>805-595-1300</phone>
    <email>gere.dizerega@usbiotest.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Claudia Bancila</last_name>
      <phone>310-423-3872</phone>
      <email>Liliana.bancila@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Simon Lo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Cancer Institute</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Zelt</last_name>
      <phone>260-266-4153</phone>
      <email>christina.zelt@parkview.com</email>
    </contact>
    <investigator>
      <last_name>Neil Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Casner</last_name>
      <phone>915-525-5822</phone>
      <email>nancy.casner@utthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Mendoza-Ladd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mercado</last_name>
      <phone>713-798-0945</phone>
      <email>Michael.Mercado@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamed O Othman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Taxol® (paclitaxel) Injection Package Insert. Bristol-Myers Squibb Company. Rev July 2011.</citation>
  </reference>
  <reference>
    <citation>ABRAXANE Package Insert. Celgene Company. Rev July 2015.</citation>
  </reference>
  <reference>
    <citation>Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.</citation>
    <PMID>24131140</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2017</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic neoplasms</keyword>
  <keyword>digestive system neoplasms</keyword>
  <keyword>pancreatic diseases</keyword>
  <keyword>digestive system diseases</keyword>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

